减重药赛道分化:辉瑞停掉研发项目 博瑞医药股价创新高

每日经济新闻
Aug 06

这两天,减重药赛道特别热闹。8月6日,诺和诺德发布半年报,今年上半年,司美格鲁肽销售额为1127.56亿丹麦克朗(约合166.32亿美元),占诺和诺德总营收的73%,基本已提前锁定“全球药王”。其中,减重版Wegovy销售额为368.88亿丹麦克朗(54.41亿美元),同比增长78%。同一天,博瑞医药(688166.SH,股价114元,市值481.96亿元)股价创新高,报收于114元/股。消息面上...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10